Companies › Theriva Biologics
1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SYN-004 Recombinant class-A beta-lactamase that hydrolyzes beta-lactam rings of susceptible antibi | – | Phase 1 | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04692181 | SYN-004 | Phase 1 | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant | Immunology | Sep 2029 |
Cash of $11m on 2026-06-30; operating cash outflow about $11m a year; runway about 12 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.